A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
Non-Small Cell Lung Cancer
Description of clinical usage of nivolumab in previously treated NSCLC patients, Approximately 9 months|Overall Survival (OS), Measured from time of initial diagnosis and treatment with nivolumab until date of death, Approximately 9 months|Progression Free Survival (PFS), Time since index date (initial diagnosis and treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first, Approximately 9 months
Percentage of patients receiving bi-weekly nivolumab, Approximately 9 months|Percentage of patients receiving monotherapy or combination therapy, Approximately 9 months|Percentage of patients receiving nivolumab as second or later line of therapy, Approximately 9 months|Median treatment duration and range by line and histology, Approximately 9 months|Rate of permanent and temporary discontinuations, Approximately 9 months|Reasons for discontinuation of nivolumab, Approximately 9 months|Reasons for re-challenge of nivolumab, Approximately 9 months|Objective Response Rate (ORR) as assessed by investigator, ORR is defined as the number of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) divided by the total number of participants who received treatment, Approximately 9 months
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan